Sedana Medical receives approval in Germany
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has received market approval for inhaled sedation in Germany.The approval applies to the drug Sedaconda (isoflurane) for administration via the medical device AnaConDa (undergoing name change to Sedaconda ACD) for inhaled sedation in intensive care in Germany. The application has been approved by the German pharmaceutical authority BfArM and is based on the DCP approval Sedana Medical received in July. Since the European DCP approval in July 2021, Sedaconda (isoflurane) has now received national approvals in